OraSure Technologies (OSUR) Earning Somewhat Positive Media Coverage, Analysis Shows

News stories about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OraSure Technologies earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 45.318041229166 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

OSUR has been the subject of several research analyst reports. Zacks Investment Research lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Jefferies Group reaffirmed a “buy” rating and set a $20.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 12th. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 19th. Finally, BidaskClub raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $19.65.

OraSure Technologies (OSUR) opened at $18.34 on Wednesday. OraSure Technologies has a 52-week low of $8.39 and a 52-week high of $23.01. The company has a market cap of $1,110.00, a P/E ratio of 35.27, a P/E/G ratio of 3.63 and a beta of 1.28.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The firm had revenue of $42.30 million during the quarter, compared to analyst estimates of $40.87 million. During the same quarter in the prior year, the business posted $0.11 earnings per share. OraSure Technologies’s revenue for the quarter was up 31.0% compared to the same quarter last year. research analysts predict that OraSure Technologies will post 0.42 earnings per share for the current fiscal year.

In other news, CEO Douglas A. Michels sold 25,000 shares of the stock in a transaction on Friday, September 29th. The shares were sold at an average price of $22.55, for a total value of $563,750.00. Following the completion of the sale, the chief executive officer now owns 743,058 shares of the company’s stock, valued at $16,755,957.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Douglas A. Michels sold 22,923 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total transaction of $527,229.00. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “OraSure Technologies (OSUR) Earning Somewhat Positive Media Coverage, Analysis Shows” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2017/12/27/orasure-technologies-osur-earning-somewhat-positive-media-coverage-analysis-shows.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

What are top analysts saying about OraSure Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OraSure Technologies and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit